WeVote
Log In

Bill

Bill

SB 2960

INS-LUNG CANCER & BIOMARKER

104th Regular Session Introduced by Adriane Johnson and 3 co-sponsors

SB 2960 mandates Illinois health insurance coverage for lung cancer biomarker testing, affecting screening access and diagnostic standards statewide.

0
WeVote Research Nonpartisan
Bill Summary · SB 2960

Legislative bill overview

SB 2960 appears to address insurance coverage for lung cancer screening and biomarker testing in Illinois. Based on the title, it likely mandates or regulates how health insurance plans cover diagnostic biomarker tests used to identify lung cancer risk factors or treatment options. The bill was recently introduced and is in early legislative stages.

Why is this important

Lung cancer remains one of the leading causes of cancer deaths, and biomarker testing can help identify patients who would benefit most from preventive screening or targeted treatments. Insurance coverage requirements directly impact patient access to these diagnostic tools and can influence treatment outcomes. This type of legislation affects both patient care pathways and insurance industry costs in Illinois.

Potential points of contention

  • Coverage mandate costs: Insurance carriers may argue that mandating biomarker test coverage increases premiums for all policyholders, while supporters contend early detection saves money long-term
  • Medical necessity standards: Disagreement over which specific biomarker tests should be covered and for which patient populations (broad vs. narrow eligibility criteria)
  • Access equity: Questions about whether coverage requirements adequately serve underinsured populations or if they primarily benefit those already well-insured

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.